Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) nonsmall cell lung carcinoma: A phase II multicenter study

Cancer

Volumn 98, Issue 8, 2003, Pages 1707-1715

  De Marinis, Filippo ^a   Nelli, Fabrizio ^b   Migliorino, Maria Rita ^a   Martelli, Olga ^a   Cortesi, Enrico ^b   Treggiari, Stefano ^a   Portalone, Luigi ^a   Crispino, Carlo ^c   Brancaccio, Luigi ^c   Gridelli, Cesare ^d  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

Author keywords

Cisplatin; Gemcitabine; Induction chemotherapy; Nonsmall cell lung carcinoma; Paclitaxel; Stage IIIA(N2)

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; GEMCITABINE; PACLITAXEL; PROMETHAZINE; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; THORACOTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR BIOPSY; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 0141923858     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11662     Document Type: Article

References (31)

1. Mountain CF. Revisions in the International System for Staging Cancer. Chest. 1997;111:1710-1717.
2. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18: 2981-2989.
3. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987;67:1037-1049.
4. Edelman MJ, Gandara DR, Roach M III, et al. Multimodality therapy in Stage III non-small cell lung cancer. Ann Thorac Surg. 1996;61:1564-1572.
5. European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, treatment, and follow-up of non-small cell lung cancer (NSCLC). Ann Oncol. 2001;12:1049-1050.
6. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for Stage III unresectable non-small cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol. 1992;10:580-586.
7. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for Stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55: 1365-1373.
8. Pujol JL, Hayot M, Rouanet P, et al. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small cell lung cancer. Chest. 1994;106:1451-1455.
9. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of Cancer and Leukemia Group B Protocol 8935. A multi-institutional Phase II trimodality trial for Stage IIIA(N2) non-small cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg. 1995;109: 473-483; discussion, 483-485.
10. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997;17:147-161.
11. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med. 1994;330:153-158.
12. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable Stage IIIA non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
13. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992-998.
14. Bunn PA Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of literature and future directions. Clin Cancer Res. 1998;4:1087-1100.
15. Van Zandwijk N. Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer. 2001;34(Suppl 2):S145-S150.
16. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small cell lung cancer. A Phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol. 1999;17:2316-2325.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
18. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1-10.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (Stage III) non-small cell lung cancer. Semin Oncol. 2001;29(Suppl 12):10-16.
21. Strauss GM, Langer MP, Elias AD, et al. Multimodality treatment of Stage IIIA non-small cell lung cancer: a critical review of literature and strategies for future research. J Clin Oncol. 1992;10:829-838.
22. Albain KS. Induction chemotherapy or chemoradiotherapy before surgery for non-small cell lung cancer. Curr Oncol Rep. 2000;2:54-63.
23. Strauss GM, Hemdon JE, Shermann DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in Stage IIIA carcinoma of the lung: report of a Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1992;10: 1237-1244.
24. Albain K, Rusch V, Crowley J, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for Stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J Clin Oncol. 1995;13:1880-1892.
25. Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accellerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a Phase II trial. J Clin Oncol. 1998;16:622-634.
26. Thomas M, Rübe C, Semik M, et al. Chemotherapy and subsequent twice-daily chemoradiation before surgery in Stage III non-small cell lung cancer: impact of tumor regression on survival. J Clin Oncol. 1999;17:1185-1193.
27. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor-downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in Stage IIIA non-small cell lung cancer. J Clin Oncol. 1997;15:712-722.
28. Van Zandwijk N, Smit EF, Kramer GW, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsyproven Stage IIIA N2 non-small-cell lung cancer: a Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol. 2000;18:2658-2664.
29. Migliorino MR, De Marinis F, Nelli F, et al. A 3-week schedule of gemcitabine and cisplatin as induction chemotherapy for Stage III non-small cell lung cancer. Lung Cancer. 2002; 35:319-327.
30. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable Stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247-253.
31. Casal J, Lazaro M, Firvida JL, et al. A Phase II Galician Lung Cancer Group Study: induction chemotherapy with taxol® (T), cisplatin, gemcitabine (G) and subsequent radiation therapy with or without concomitant taxol® for Stage III non small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:330a.